Editorial Staff

As COVID-19 Emergencies Ease, Some Progress on Telehealth Rules

/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

BOSTON, MA (Feb. 15, 2023) — As public health emergency declarations related to the COVID-19 pandemic come to an end, a new study from Pioneer Institute, Cicero Institute, and Reason Foundation rates every state’s telehealth laws. The report finds Arizona and Delaware rate best across four key telehealth policy areas, while highlighting some progress in New England.

Legislation in Vermont creates a clear path to allow out-of-state providers to see Vermont patients, although some barriers to access remain; in New Hampshire, new legislation gives a green light to providers to start a telehealth visit by any mode that works for them and their patients. While Massachusetts scores a “green” rating on three of the measures, the state continues to bar access to telehealth services across state lines.

With the three-year COVID-19 pandemic largely under control, the Biden administration recently announced plans to end the COVID-19 national public health emergency on May 11. Most states have already ended their public health emergency declarations, so the temporary orders and waivers that allowed millions of patients to access telehealth services during the pandemic need to be turned into permanent laws, or patients risk losing access to healthcare options and providers may lose significant incentives to innovate, a new report warns.

The policy brief rates all 50 states in four critical areas of telehealth policy and details what each state needs to do to improve.

Arizona and Delaware stand out as the only two states rated green for good in all four key telehealth law categories related to enabling patients to access high-quality telehealth care and giving healthcare providers the flexibility to provide a variety of services now and in the future. In contrast, three states—New Jersey, South Carolina, and Virginia—fail to score green in any of the four categories the report deems critical to today’s telehealth services and future innovation.

The report grades every state’s telehealth laws in four areas crucial to patients, quality of care, and creating a regulatory environment that doesn’t stifle future healthcare improvements. It recommends that states:

  • Should define telehealth in broad terms that do not favor one type of telehealth model, giving current patients options and leaving room for future innovations.
  • Allow modal neutrality so services can be provided via audio, video, text, email, and other modes of communication.
  • Allow patients to access telehealth services, doctors, and providers across state lines.
  • Allow doctors, nurse practitioners, and others to provide all the medical services they’re trained to provide.

“A surprising number of states have only made minor tweaks to their telehealth laws,” said Josh Archambault, coauthor of the policy brief and senior fellow at Pioneer Institute and the Cicero Institute. “Lawmakers must refocus their efforts to ensure their states have clear laws and guidelines in place so that patients and providers can benefit from today’s telehealth services and future innovations.”

“During the COVID-19 pandemic, patients discovered and utilized a variety of telehealth options that offered flexible, affordable, and high-quality care, and those options shouldn’t be taken away,” added Vittorio Nastasi, coauthor and a policy analyst at Reason Foundation. “States need to improve their laws so patients have as many quality care options as possible and the future healthcare system can become more patient-centric.”

The full report, State Policy Agenda for Telehealth Innovation, also outlines how each state can modernize and upgrade its telehealth laws without stifling future advancements.

Contact

Josh Archambault at (617) 645-7679 or jarchambault@pioneerinstitute.org

Get Updates On Our Healthcare Research and Events!

Related Posts:

Building Healthcare Bigger: New Bill Is Good Medicine or Ill-Designed Cost Shift

This week on Hubwonk, host Joe Selvaggi talks with Josh Archambault, Pioneer Institute’s Senior Fellow in Healthcare, about the healthcare provisions in the pending Build Back Better Act and their likely impact on the coverage and cost to Americans in the wake of Covid-19.

The Promise and Challenges of Rare Cancer Treatments

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

COVID’s Unintended Victims: Traditional Diseases Overlooked at the Public’s Peril

This week on Hubwonk, host Joe Selvaggi talks with Pioneer Institute’s Visiting Fellow in Life Sciences, Dr. Bill Smith, about his newest research paper, “An “Impending Tsunami” in Mortality from Traditional Diseases,” which sounds the alarm that the public health community’s focus on COVID-19 has caused many to avoid seeking medical attention for other illnesses. As a result, more Americans are dying from fear of COVID than from the disease itself.

Vaccine Development Renaissance: Pandemic Brings Niche Industry into Mainstream

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

Shifting COVID-19 Goalposts: Moving from Zero Infections to Zero Deaths

This week on Hubwonk, host Joe Selvaggi talks with surgeon and author Dr. Marty Makary about the power and durability of vaccines, natural immunity and clinical therapies, that are overshadowed by the public health community's continued target of zero COVID-19 infections.
A Woman Helping a Disabled Man in a Wheelchair

An Act advancing health care research and decision-making centered on patients and people with disabilities

On November 9th, 2021, William Smith, Pioneer Institute Visiting Fellow in Life Sciences, submitted the following testimony to the Massachusetts Legislature in support of House Bill 201, which addresses a number of flaws and infirmities in the Quality Adjusted Life Years (QALYs) methodology that is utilized by a number of foreign nations in evaluating the value of medicines.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.